Biomedical researchers at the Lampe Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill/North Carolina State University, have developed an injectable microgel designed to significantly reduce bleeding in infants undergoing surgical procedures. In animal model tests, these hemostatic microgels, termed B-knob-triggered microgels (BK-TriGs), demonstrated a reduction in bleeding by at least 50%.
Research lead Ashley Brown, PhD, highlighted that this innovation addresses the unique hemostatic challenges faced by neonates, who are at a heightened risk of bleeding and thrombosis during surgery. The findings, published in Science Advances, suggest that BK-TriGs could provide a tailored solution to improve hemostasis in this vulnerable population, potentially reducing reliance on adult blood transfusions, which pose significant safety concerns.
Current practices often involve transfusing adult blood products, which can lead to complications due to the structural differences in clotting mechanisms between adults and infants. The BK-TriGs, engineered to mimic the natural clotting process in neonates, have shown promise in enhancing clot density and stability. As the research progresses, further studies will be crucial in evaluating the clinical utility of BK-TriGs compared to existing hemostatic therapeutics.
Open the full market picture for your next decision →
